Who is sponsoring NCT05998915?

NCT05998915 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT05998915?

Interventions in NCT05998915: observe only.

What condition does NCT05998915 study?

NCT05998915 studies Human Microecology；Colorectal Disease；Auxiliary Diagnosis.

Is NCT05998915 still recruiting?

NCT05998915 is currently status unknown. Last updated 29 November 2023.

Last reviewed 2023-11-29 · How we verify

NCT05998915

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-center Study on Human Microecology Assisted Diagnosis of Colorectal Cancer

Status unknown Last updated 29 November 2023

What this trial tests

trial testing observe only in Human Microecology；Colorectal Disease；Auxiliary Diagnosis in 5 participants. Status unknown.

Timeline

1 March 2023

Primary endpoint
30 December 2025

31 December 2025

Quick facts

Lead sponsor	Zhujiang Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	5
Start date	1 March 2023
Primary completion	30 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

observe only

Conditions studied

Human Microecology；Colorectal Disease；Auxiliary Diagnosis — all drugs for Human Microecology；Colorectal Disease；Auxiliary Diagnosis →

Sponsor

Zhujiang Hospital

Who can join

Eligibility, any sex, with Human Microecology；Colorectal Disease；Auxiliary Diagnosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As for this research，we want to find whether the intestinal microecology (flora, peptidoglycan fragments) have certain distribution characteristics in colorectal diseases; whether it can predict the development of disease/as a prognostic indicator.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05998915 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 29 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05998915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing